Evidence Hub

Vonoprazan pharmacokinetics and effects on gastric pH following administration to fed and fasted horses

Camilo J. Morales, Ben William Sykes, Daniel S. McKemie, Philip H. Kass, Heather K. DiMaio Knych

Equine Veterinary Journal, 2026

1 citation

Abstract

BACKGROUND: Current treatment options for equine gastric ulcer syndrome (EGUS), such as omeprazole-a proton pump inhibitor (PPI)-have notable limitations, including the need for administration on an empty stomach. Potassium-competitive acid blockers (P-CABs), such as vonoprazan, are a newer class of acid suppressants that offer several advantages over PPIs in humans and may provide similar benefits in horses. OBJECTIVES: To describe the pharmacokinetics and effect of a single oral dose of vonoprazan on intragastric pH in horses. We hypothesised that vonoprazan would follow linear kinetics across the doses studied and effectively increase intragastric pH. STUDY DESIGN: Prospective, randomised four-way balanced crossover study. METHODS: Six horses received vonoprazan (0.5 and 1 mg/kg), omeprazole (4 mg/kg) and water (60 mL). Blood samples were collected prior to and up to 72 h post-administration. Plasma vonoprazan concentrations were measured using liquid chromatography-tandem mass spectrometry, and non-compartmental and compartmental pharmacokinetic analyses were performed. Intragastric pH was continuously recorded 12 h before and 24 h after each treatment. The percentage of time pH remained above 4 was compared among treatments. RESULTS: was 0.875 (0.25-3.0) and 0.625 (0.08-1.0) h (median and range); and terminal half-life was 6.12 ± 1.65 and 6.29 ± 1.86 h (mean ± SD). At 1 mg/kg, vonoprazan significantly increased the percentage of time pH >4 compared to pre-treatment…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free